The U.S. Food & Drug Administration has cleared Insulin Algorithms’ decision-support software, which helps clinicians manage every type of insulin for diabetes treatment.
Short on time? Here’s a short video. Or you can explore our website for detailed information about the diabetes epidemic, the endocrinology care gap, and our solution.
Optimized Insulin Dosing for Every Patient
Expand Access To Care
Primary care physicians, nurses, and other care providers can now create and manage insulin-dosing regimens with precision.
Works with all insulin types and regimens
Our solution is not limited to specific regimens or only certain types of insulin. Providers can work from any insulin regimen to create optimal dosing for their patients.
Clinically proven to lower HbA1c and costs of care
Clinically optimal dosing leads to lower HbA1c and fewer complications from diabetes.
How It Works
Our software uses glucometer data to deliver optimized, patient-specific insulin dosing recommendations in seconds. Here’s how.
Clinically Proven Algorithms
Our protocols were developed over 30 years by our Chief Medical Officer, Dr. Mayer B. Davidson, MD.
Maintained avg. HbA1c
in 400 inner city, insulin-requiring patients
Our algorithms maintained a 7.7% average HbA1c in a difficult to manage population of low-income, insulin-requiring patients. Blood sugar control varies by income.
Dropped HbA1c from 11% to
in 110 patients in one year
In a published study of a nurse managing 110 patients with our algorithms, HbA1c’s were reduced from an initial average value of 11.0% to 7.2% in just one year.
Lowered HbA1c From 8.4% to
in 30 patients in 20 weeks
In a published study of remote monitoring of 30 patients with diabetes, our algorithms were used to lower HbA1c levels from 8.4% to 7.7% in just 20 weeks.
“After hearing the presentation describing your computerized insulin dose adjustment algorithms, we are very interested in evaluating them. The initial evaluation of 10 patients seemed very promising. For this reason, we look forward to working with you in the future as we develop the way in which our two systems can electronically interact.” R. James Dudl, MD | Diabetes Lead Care Management
“Our Diabetes program utilizes clinical pharmacists to aid in the treatment of our diabetic patients…Therefore we would be very interested in evaluating your insulin dose adjustment algorithms after they receive 510 (k) clearance. Please let us know when this occurs.” Stephen Deutsch, MD | Chief Medical Officer
“We were quite impressed with its clinical effectiveness and clearly see how this solution and tool will help our overworked primary care providers do a much better job of lowering HbA1cs for our insulin-requiring diabetic patients.” Sunday Irene, MD | Chief Medical Officer
Deep Medical, Management, Software, and Technical Expertise.